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would tremendously decrease the number of related illnesses and deaths, thereby significantly reducing costs of related medical interventions for these illnesses and enhancing health benefits. Although efficacy of the influenza and pneumococcal vaccines are less impressive than the aforementioned immunobiologics, consistent use in specific at risk populations (e.g., the elderly and individuals with chronic illnesses) would help to reduce devastating manifestations of the respective diseases, such as influenza pneumonia and pneumococcal septicemia (ACP & IDS, 1994) . Thus, significant health benefits gained from these vaccines would justify the related costs.
RECENT INITIATIVES
Notable governmental and health care professional guidelines have been articulated for the purpose of aggressively enhancing vaccination rates and reducing vaccine related adverse effects in the United States population (ACP & IDS, 1994; CDC, 1991a CDC, ,b, 1994 National Coalition for Adult Immunization, 1992; USDHHS, 1992 USDHHS, , 1994 . From these initiatives have evolved: • A widely accepted across the lifespan vaccine schedule.
• Well articulated goals and objectives for the purpose of eliminating selected vaccine related diseases (which includes but is not limited to tetanus, diphtheria, measles, rubella, and hepatitis B) and reducing devastating sequelae related to influenza and pneumococcal pneumonia. • National standards for assuring safe and effective immunizations for the adult populace. • General recommendations for: assuring safe handling and administration of immunobiologics; enhancing acceptance and availability of vaccines; and reducing barriers to successful adult immunization (e.g., monetary cost).
As a result, clinicians now have a framework and clinical tools to support the implementation of common immunization programs.
FRAMEWORK FOR IMMUNIZATION DELIVERY
As suggested in the previous section, the success of vaccine delivery is significantly influenced by various interconnected biopsychosocial variables. To translate these factors into well organized and clinically relevant guidelines, it is important for the clinician to have a sound understanding of pertinent disease epidemiology, vaccine specific factors, health care provider characteristics, and health behavior concepts that influence the strategies for vaccine delivery and the ultimate outcome: safe and effective vaccine delivery (Finn, 1991; Rosenstock, 1988) . JULY 1996, VOL. 44, NO.7 
Disease Epidemiology
Successful artificial immunity is contingent on a number of host and contagion variables. Important host considerations that may influence immunity are: • Age and/or health status. Old age and/or an altered immune status may significantly blunt an antibody and/or antitoxin response to the agent. • Hypersensitivity status. Allergic reactions to an immunobiologic or the related by products, such as traces of neomycin in the measles-rubella (M-R) vaccines, may necessitate discontinuation of a particular immunobiologic, thus diminishing the host's ability to resist the respective infection.
• Pregnancy status. The theoretical risk of teratogenic effects from selected immunizations, particularly live vaccines (e.g., M-M-R vaccines) necessitates avoiding certain vaccines during pregnancy. Consequently, the host may be more vulnerable to vaccine-related diseases given incomplete or absent immunity.
A number of contagion specific factors influence successful immunization. Most notably, the degree of diversity of the virulent antigens of a microorganism, which are used to produce live and inactivated vaccines, greatly determines the effectiveness of the related immunobiologic. Antigenic diversity is one of the reasons why certain vaccines, for example a human immunodeficiency virus (HIV) vaccine, have not been developed yet and why well established immunobiologics, such as the influenza vaccine, are less effective than other commonly utilized vaccines.
Other contagion variables that significantly influence effective vaccine delivery are incidence rates of the vaccine related illness, mode of transmission of the respective microorganism, morbidity and mortality rates, infectious reservoirs and carriers, and pathogen interference (e.g., the live attenuated typhoid vaccine may theoretically interfere with the immune response to the oral polio vaccine) (Finn, 1991) . An example of a vaccine that underscores the importance of these epidemiologic characteristics in the context of prevention and ultimate eradication of an infection is the smallpox immunization.
In the last century, smallpox was one of the leading causes of death with worldwide incidence. It was a disease spread from human to human (no other infectious reservoirs) via close contact with an infected individual (no asymptomatic carrier state). The endemicity, confined transmission, and infectious reservoir, coupled with limited antigen diversity of the microorganism, led to the successful prevention and ultimate elimination of the infection (Finn, 1991) . The last case of smallpox was documented in 1979 (Friedman, 1991) .
Vaccine Specific Factors
The following vaccine-specific variables help to determine the potency and safety profiles of immunobiologics:
• Active and inactive ingredients of the immunization. Certain adjuvants may heighten the immunogenicity of the vaccine; and certain suspending fluids, preservatives, stabilizers and/or antibiotics may evoke hypersensitivity reactions in the host.
• Storage and handling of the immunobiologics. • Administration factors (appropriate route, site, and dose of the vaccine).
• Spacing of the immunizations (appropriate interval and simultaneous administration of immunobiologics).
• Mandatory reporting of adverse effects to the Vaccine Adverse Events Reporting System (VAERS) (to document and track adverse events that would influence the utilization patterns of a respective immunobiologic) (CDC, 1994) .
Health Care Provider Characteristics
A successful immunization campaign is very much contingent on the knowledge and skills of the clinician about vaccination selection and administration. However, often, little consideration is given to the factors that influence whether a practitioner recommends or discourages this disease prevention activity. Reasons for encouraging or discouraging vaccine delivery by practitioners are: perceptions or misperceptions about vaccine contraindications and adverse effects; time variables that influence the implementation of prevention strategies; ability/inability to recall the immunization status of the respective individual; and reimbursement for immunization administration (USDHHS, 1994) .
Ongoing professional education and training about vaccine delivery is crucial. Also, attention to important environmental variables that significantly influence provider behaviors/recommendations (e.g., tracking methods for clinical preventive services) is imperative (see next section).
Health Behavior Factors
Numerous researchers have noted that disease prevention activities, such as immunization programs, are likely to be accepted by individuals, and therefore successful, if: • The targeted population perceives itself to be at risk for the respective illness and related illness outcomes. • Actual and/or perceived barriers (e.g. monetary cost, inconvenience, fear of adverse effects) to vaccination are reduced.
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• The target population perceives the benefits of immunization to be greater than the limits associated with immunizations.
• The preferred outcome(s) (e.g., improved health status, peer approval) is/are reinforced on an individual, community, and/or societal basis (Pender, 1987; Rosenstock, 1988) .
Multiple educational and environmental (i.e., organizational and sociopolitical) strategies are needed to assure the acceptance and delivery of vaccinations. Selected educational/informational strategies that may highlight appropriate risk perception and underscore healthy behaviors are: • Postcard reminders to employees who are in need of vaccination (e.g., older employees at risk for influenza). The reminder could briefly identify the necessity for immunization and the relevant benefits (Mullooly, 1987) . • Individual risk factor assessments with analyses (USDHHS, 1994). • Personal health records.
• Community based interventions, e.g., media campaigns.
A number of environmental/organizational strategies could help reduce significant barriers to effective vaccine delivery. One valuable tactic would be to implement a well organized and standardized health protection checklist, which would include an area for an immunization history within the employee's health records. This type of standardized tracking system has been shown to reinforce health protection practices among providers in ambulatory care settings (Cheney, 1987) .
Additional strategies to be considered are interventions to reduce the cost of vaccinations for the immunization recipients, especially high risk individuals* and to enhance accessibility to vaccine delivery systems through the use of non-traditional vaccination centers (e.g., worksites, nursing homes, and churches) (CDC, 1991a) . Finally, and probably most importantly, is to frame these interventions in the context of a target population based approach whereby organizations very explicitly track immunization rates for high risk populations (e.g., influenza vaccination rates for the older employee) (CDC, 1991a) .
Important organizational/sociopolitical strategies *Note: as of 1991, employees at risk for hepatitis B should be able to receive the respective vaccine at the expense of the employer (Department of Labor, Occupational Safety and Health Administration, 1991) , and enhancing accessibility to vaccine delivery systems through the use of non-traditional vaccination centers (e.g., worksites, nursing homes, and churches) (CDC, 1991a) .
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that would support an immunization campaign would be to widely disseminate immunization information within the worksite and the community at large via formal/informal presentations, newsletters, and community forums. This type of exposure heightens the level of awareness and import for this crucial disease prevention activity. In sum, safe and effective vaccine delivery is contingent on the coordination of important epidemiologic factors so that the correct protection strategy against the specific vaccine related disease is selected for the appropriate groups of individuals. Additionally, an ample understanding of and attention to vaccine specific factors, provider variables, and behavioral principles will ultimately lead to an acceptance of the immunization(s) as well as a safe delivery of the immunobiologic(s).
IMMUNIZATION REVIEW (TABLE 2)
Toxoids: Tetanus and Diphtheria These toxoids are available in three formulations for adults: tetanus and diphtheria toxoids adsorbed form adult use (Td), tetanus toxoid (T), and tetanus toxoid (fluid). Most authorities recommend the combined Td immunization primary series (three vaccinations, spaced accordingly) and booster (vaccination every 10 yearas after the primary series) given the overall low diphtheria antitoxin antibody levels in the adult population (ACP & IDS, 1994; CDC, 1994) . In general, the Td vaccination may safely be administered at the same time as live and inactivated vaccines, but at a separate site. Overall, it is a well tolerated vaccination with few significant adverse reactions. To avoid an Arthus-type hypersensitivity to the tetanus toxoid (severe local reactions, fever, and malaise within hours after administration), the immunization should be given no more than every 5' years after the primary series.
Live Virus Vaccines: Measles, Mumps, and Rubella
These vaccines are available in monovalent forms or in combinations (M-R or M-M-R vaccines). As the trivalent immunization is overall well tolerated by most hosts, even with revaccination (a two dose series of the measles vaccine is the customary schedule), the M-M-R vaccine is recommended, unless the host is allergic to one of -the vaccines and/or related components. Utilizing the M-M-R vaccine would eliminate the cost of laboratory documentation for rubella immunity. Arthralgias and arthritis like symptoms are the most commonly reported side effects (related to the rubella vaccine), and they occur approximately 1 to 3 weeks post-vaccination (USDHHS, 1994) . These symptoms abate within 1 day to 3 weeks and rarely recur (ACP & IDS, 1994) . Both monovalent and trivalent vaccines may be safely administered simultaneously with toxoids and/or inactivated vaccines. However, live vaccines should be administered at least 2 weeks before or 6 to 12 weeks after the administration of immune globulins so as to avoid any interference with appropriate antibody production to the respective antigen (CDC, 1991b) .
Inactivated Virus Vaccine: Hepatitis B
There are two types of recombinant derived hepatitis B vaccines (Recombivax HB and Engerix-B). The primary schedule of both immunobiologics is a tri-dose series. Both vaccines may be given simultaneously with toxoids, live vaccines, and immune globulins, but at a separate site.
To maximize seroconversion, the vaccine should be administered in the host's deltoid muscle rather than the buttocks (lower seroconversion rates occur when the vaccine is administered in the buttocks because of deposition ofthe agent in fat) (USDHHS, 1994 (1990) . Used by special permission of the publisher.
tAGP & (1994) . §Individuals at risk for 1Mhemorrhage (e.g., persons with thrombocytopenia and individuals on anticoagulants) should only receive this immunobiologic under the direct supervision of their regular health care provider. +May be given as combined measles-rubella vaccine or measles-mumps-rubella vaccine (M-M-R-II-MSO).
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sular polysaccharides of 23 pneumococcal strains which are responsible for 85% to 90% of bacteremia infections (ACP & IDS, 1994) . PPV should be administered once in the healthy elderly population. Revaccination 6 years after the initial dose is recommended for individuals at highest risk for fatal pneumococcal infection (e.g., asplenic individuals) and for persons who have rapid decreases in circulating antibody levels (e.g., individuals with chronic renal failure or transplanted organs) (ACP & IDS, 1994) .
Since the vaccine is inactivated, it may be safely administered with other inactivated vaccines (e.g., influenza vaccine) or toxoids, live vaccines, or immune globulins. However, the vaccine should be administered at a separate site either intramuscularly or subcutaneously.
Erythema and pain at the injection site are common side effects, but resolve in less than 2 days following administration. Avoiding unnecessary revaccination with special attention to appropriate spacing of doses would essentially eliminate Arthus like reactions (severe local reactions, fever, and malaise within hours after administration).
NEWLY APPROVED VACCINES FOR ADULTS (TABLE 3)

Inactivated Virus Vaccine: Hepatitis A
This vaccine has been prepared in human cell cultures and is formalin inactivated. It has been licensed for use since the beginning of 1995. Because it is an inactivated immunobiologic, it may be safely administered with live vaccines, other killed vaccines, and immune globulins, but at a different site.
The populations who should be targeted for administration are: international travelers; day care and custodial care workers; persons with multiple sexual partners; close contacts of people infected with the hepatitis A virus (HAV); and populations with high HAV infection rates (e.g., Alaskan Natives and American Indians). An effective humoral antibody response has been estimated to be around 80% to 98% in individuals vaccinated with one dose of the HAV immunization (Hepatitis A vaccine, 1995) . Antibody levels are enhanced and likely to be better sustained if the host receives a second dose 6 to 12 months after the initial administration.
The most common side effect is soreness at the injection site. Other uncommon adverse effects are headache, fatigue, fever, malaise, anorexia, and nausea. Anaphylactic reactions have been reported rarely during the trial periods from 1979 to 1994. As this vaccine is relatively new, clinicians are strongly encouraged to report CE ART I C L Ẽ Letter (1995a,b) all significant adverse reactions to VAERS and avoid the use of this agent in pregnant women.
Live Virus Vaccine: Varicella
From trials conducted predominantly in other countries, this live virus vaccine has been very well tolerated. JULY 1996, VOL. 44, NO.7 Seroconversion rates among adult hosts were reported to be 82% after one dose and 94% after two doses, respectively (Varicella vaccine, 1995) . However, clinical disease may still occur following an exposure, despite appropriate vaccination. Fortunately, the clinical disease in vaccinated individuals is reported to be milder in vac-cinees than non-vaccinated individuals .
This immunization is recommended for all adults with no history of the disease, as varicella disea se is especially serious in the adult population. However, special attention should be given to individuals who have close contact with susceptible high risk populations who would suffer grave complications from the disease (e.g., health care workers in contact with immunocompromised individuals). Given the risk of potential infection, the vaccine should not be administered to: immunocompromised individuals; persons with blood dyscrasias, lymphoma, and leukemia; and pregnant women or women planning to become pregnant within 3 months of administration. Also, this agent should not be given to persons with neomycin hypersensitivity or known hypersensitivity to vaccine components or to adolescents (and younger children) who are taking salicylates, given the risk of Reyes syndrome (salicylates should be avoided for 6 weeks following administration) (USDHHS, 1994) .
This immunobiologic should be administered at least 2 weeks before, or 6 to 12 weeks after, the administration of immune globulins to avoid any interference with appropriate antibody production to the respective antigen by the host (CDC, 1991b) . The vaccine may be safely administered with the M-M-R vaccine. Investigations are currently in place to assess the safety and efficacy of a multiple antigen measles-mumpsrubella-varicella vaccine (USDHHS, 1994) . Also, this immunobiologic may be given simultaneously with toxoids, but at a separate site.
Common side effects include tenderness and erythema at the injection site in up to 25% of vaccinees (Varicella vaccine, 1995) . Also, a maculo-papular, vesicular rash may occur in approximately 5% of vacinees (Varicella vaccine, 1995) .
CONCLUSION
Occupational health nurses, pivotal players in the battle against vaccine preventable illnesses, have the means to essentially eradicate these diseases or significantly modify their clinical sequelae. It is important for occupational health nurses to embrace these guidelines in the context of their nursing practice to design and implement worksite tailored immunization campaigns.
